Title |
MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis
|
---|---|
Published in |
Arthritis Research & Therapy, June 2016
|
DOI | 10.1186/s13075-016-1023-0 |
Pubmed ID | |
Authors |
Veronika Hruskova, Romana Jandova, Lucia Vernerova, Herman Mann, Ondrej Pecha, Klara Prajzlerova, Karel Pavelka, Jiri Vencovsky, Maria Filkova, Ladislav Senolt |
Abstract |
MicroRNAs (miRNAs) are small RNAs that regulate gene expression by targeting mRNA. It was proved that some miRNAs are significantly deregulated in rheumatoid arthritis (RA). MicroRNA-125b negatively regulates expression of TNF-α, which plays a crucial role in RA pathogenesis. The aim of this study was to determine the treatment outcome of patients with early RA based on the expression of circulating and cellular miR-125b. Total RNA was isolated from the plasma and peripheral blood mononuclear cells (PBMCs) of 58 patients with early RA before and three months after treatment initiation and of 54 age- and sex-matched healthy controls (HC). The expression of miR-125b was measured by TaqMan quantitative PCR. The treatment responders were defined as patients achieving remission or low disease activity (28-joint count disease activity score (DAS28) <3.2). Receiver operating characteristic (ROC) curve and stepwise backward multivariable logistic regression analyses of miR-125b expression were used to predict the disease outcome at three and six months after initiation of treatment. The expression of miR-125b in the PBMCs and plasma of treatment-naïve early RA patients was significantly lower than that of HC and increased significantly after three months of treatment, particularly in responders. However, only the cellular expression of miR-125b was inversely correlated with disease activity. MiR-125b expression in PBMCs was higher in responders than in non-responders after three months (p = 0.042). Using ROC analysis, the cellular expression of miR-125b, but not the disease activity at baseline, predicted the treatment response after three months of therapy (area under the curve 0.652 (95 % CI 0.510 to 0.793); p = 0.048). The expression of miR-125b in PBMCs of treatment-naïve patients may present a novel biomarker for monitoring the treatment outcome during the early phase of RA. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 2% |
Unknown | 49 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 10 | 20% |
Researcher | 9 | 18% |
Student > Master | 6 | 12% |
Student > Bachelor | 5 | 10% |
Other | 3 | 6% |
Other | 2 | 4% |
Unknown | 15 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 12 | 24% |
Medicine and Dentistry | 9 | 18% |
Agricultural and Biological Sciences | 8 | 16% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Arts and Humanities | 1 | 2% |
Other | 3 | 6% |
Unknown | 16 | 32% |